Latest News

NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria

18th June 2016

Aberdeen, UK - 18 June 2016 - NovaBiotics Ltd ('NovaBiotics' or the 'Company'), the Aberdeen-based clinical-stage biotechnology company, has presented new data showing antibiotic resistance breaking activity of cysteamine at the ASM Microbe conference, taking place in Boston, MA.

The Company presented a late breaker paper outlining how Nylexa™, its parenteral formulation of cysteamine in early stage development, improves the antimicrobial efficacy of antibiotics and reverses multi-drug resistant (MDR) infections.

The active component of Nylexa™ is cysteamine, a molecule which NovaBiotics first discovered as a multi-active antimicrobial in its research into cystic fibrosis (CF) therapy and the clinical trials of its novel CF therapy Lynovex®. The talk highlighted the much broader clinical potential of cysteamine-based products in a wider range of drug resistant and even MDR Gram negative and Gram positive bacterial infections.

NovBiotics' results show that cysteamine reverses resistance to clinically important antibiotic classes such as aminoglycosides, fluoroquinolones, macrolides, folate pathway inhibitors and beta-lactams. NovaBiotics also presented data to show that cysteamine reverses MCR-1 and other forms of colistin resistance.

Colistin resistance has recently gained much attention in the press because of its over-use in food producing animals (>12,000 tons of colistin used each year in farming). Colistin is often regarded as the antibiotic of last resort for humans against infections such as E. coli, and therefore, resistance to it is a growing public health concern.

Dr Deborah O'Neil, CEO of NovaBiotics, said: "We have previously shown that cysteamine can increase the sensitivity of pathogens to a broad range of clinically relevant antibiotics and reverses resistance in CF. Today's data shows that this molecule has a much broader utility, as an adjunct antimicrobial for MDR bacterial infections.

"We believe resistance breakers, like Nylexa™ and other forms of cysteamine have the potential, in the shorter term, to breathe new life into a clinician's existing antibiotic arsenal, extending their utility and thereby saving lives.

"For the longer term, we will continue to develop our antibacterial and antifungal therapies, Novamycin® and Novarifyn®, against which resistance development is highly unlikely."

NovaBiotics' other cysteamine product, Lynovex® (NM001), is a late stage orphan drug candidate for the treatment of Cystic Fibrosis related lung disease in oral and dry powder inhaler form. In a phase IIa clinical study, five week exposure to oral Lynovex®, in addition to standard of care antibiotic therapy, reversed single and multi-antibiotic resistance in P. aeruginosa and S. aureus isolates.

 

Older News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management | 3rd March 2017
Commercial Collaboration Deal for (Oral) Lynovex® | 5th August 2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria | 18 June 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance | 7th June 2016
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010

Latest News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
3rd March 2017

Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
7th June 2016

NovaBiotics Wins Investment of the Year Award
5th February 2016

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12th August 2015

Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium
12th June 2015

Launch of the BEAM Alliance
9th June 2015

NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19th January 2015

NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014
7th October 2014

Showcases increasing investor interest in the global stem cell sector
22nd September 2014

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex®
16th September 2014

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London
18th August 2014

Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group
25th July 2014